These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 20564872)

  • 1. [Multiple sclerosis: emerging treatments (1)].
    Nau JY
    Rev Med Suisse; 2010 May; 6(250):1098-9. PubMed ID: 20564872
    [No Abstract]   [Full Text] [Related]  

  • 2. [Alemtuzumab and multiple sclerosis].
    Nau JY
    Rev Med Suisse; 2008 Nov; 4(178):2425. PubMed ID: 19051633
    [No Abstract]   [Full Text] [Related]  

  • 3. [Multiple sclerosis. What about treatment with monoclonal antibodies?].
    Marignier R; Confavreux C
    Rev Prat; 2010 Mar; 60(3):304-6. PubMed ID: 20402115
    [No Abstract]   [Full Text] [Related]  

  • 4. [Biological treatment of multiple sclerosis].
    Sørensen PS; Sellebjerg F
    Ugeskr Laeger; 2008 Jun; 170(24):2156-9. PubMed ID: 18565303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Monoclonal antibodies and their targets in the treatment of multiple sclerosis].
    Chan A
    Drug Res (Stuttg); 2013 Nov; 63 Suppl 1():S10-1. PubMed ID: 24242028
    [No Abstract]   [Full Text] [Related]  

  • 6. Emerging monoclonal antibody therapies for multiple sclerosis.
    Cree B
    Neurologist; 2006 Jul; 12(4):171-8. PubMed ID: 16832236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Melanoma following treatment with alemtuzumab for multiple sclerosis.
    Pace AA; Zajicek JP
    Eur J Neurol; 2009 Apr; 16(4):e70-1. PubMed ID: 19222552
    [No Abstract]   [Full Text] [Related]  

  • 8. Multiple sclerosis: pathophysiology revisited.
    Sorensen PS
    Lancet Neurol; 2005 Jan; 4(1):9-10. PubMed ID: 15620850
    [No Abstract]   [Full Text] [Related]  

  • 9. Neurotherapeutics in multiple sclerosis: novel agents and emerging treatment strategies.
    DeAngelis T; Lublin F
    Mt Sinai J Med; 2008; 75(2):157-67. PubMed ID: 18500719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Daclizumab: Clinical trial of monoclonal antibody for the treatment of MS].
    Kreutzkamp B
    Med Monatsschr Pharm; 2014 Jun; 37(6):202-6; quiz 207-8. PubMed ID: 25051810
    [No Abstract]   [Full Text] [Related]  

  • 11. [Alemtuzumab in early multiple sclerosis].
    Killestein J; Polman CH
    Ned Tijdschr Geneeskd; 2009 Jan; 153(1-2):46. PubMed ID: 19198214
    [No Abstract]   [Full Text] [Related]  

  • 12. Anticipated benefits and surprising effects of daclizumab in multiple sclerosis.
    Stüve O; Greenberg BM
    Lancet Neurol; 2010 Apr; 9(4):337-8. PubMed ID: 20163991
    [No Abstract]   [Full Text] [Related]  

  • 13. [Multiple sclerosis, the therapeutic arsenal of today and tomorrow].
    Zéphir H
    Soins; 2009 Nov; (740):39-41. PubMed ID: 20014532
    [No Abstract]   [Full Text] [Related]  

  • 14. Campath-1H treatment of multiple sclerosis: lessons from the bedside for the bench.
    Coles A; Deans J; Compston A
    Clin Neurol Neurosurg; 2004 Jun; 106(3):270-4. PubMed ID: 15177782
    [No Abstract]   [Full Text] [Related]  

  • 15. [Immune mechanisms and novel therapeutic targets for ITP].
    Kuwana M; Ikeda Y
    Rinsho Ketsueki; 2005 Feb; 46(2):99-103. PubMed ID: 16447702
    [No Abstract]   [Full Text] [Related]  

  • 16. Multiple sclerosis therapies: molecular mechanisms and future.
    Fontoura P; Garren H
    Results Probl Cell Differ; 2010; 51():259-85. PubMed ID: 20838962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Development of new therapies for multiple sclerosis].
    Holmøy T; Celius EG
    Tidsskr Nor Laegeforen; 2011 May; 131(8):832-6. PubMed ID: 21556088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase III clinical trial using daclizumab for relapsing-remitting multiple sclerosis initiated.
    Immunotherapy; 2010 Jul; 2(4):437. PubMed ID: 20635996
    [No Abstract]   [Full Text] [Related]  

  • 19. End of the road for daclizumab in multiple sclerosis.
    The Lancet
    Lancet; 2018 Mar; 391(10125):1000. PubMed ID: 29565004
    [No Abstract]   [Full Text] [Related]  

  • 20. Alemtuzumab versus interferon beta-1a: implications for pathology and trial design.
    McFarland HF
    Lancet Neurol; 2009 Jan; 8(1):26-8. PubMed ID: 19081510
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.